Cargando…

Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment

BACKGROUND: Multiple myeloma (MM) is a plasma cell malignancy frequently associated with impaired immune cell numbers and functions. In MM, several studies have previously shown that CD4 regulatory T (Treg) cells hamper effector T cell functions and enhance immune dysfunction. In this study, we aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muthu Raja, Karthick Raja, Kubiczkova, Lenka, Rihova, Lucie, Piskacek, Martin, Vsianska, Pavla, Hezova, Renata, Pour, Ludek, Hajek, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496705/ https://www.ncbi.nlm.nih.gov/pubmed/23152910 http://dx.doi.org/10.1371/journal.pone.0049446

Ejemplares similares

Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
por: Muthu Raja, Karthick Raja, et al.
Publicado: (2012)

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
por: Knight, Andrea, et al.
Publicado: (2021)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
por: Raja, Karthick Raja Muthu, et al.
Publicado: (2013)

Do human B-lymphocytes avoid aging until 60 years?
por: Knight, Andrea, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
por: Bezdekova, Renata, et al.
Publicado: (2021)

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
por: Vlachová, Monika, et al.
Publicado: (2022)

TGF-β – an excellent servant but a bad master
por: Kubiczkova, Lenka, et al.
Publicado: (2012)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
por: Kryukov, Fedor, et al.
Publicado: (2016)

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
por: Dementyeva, Elena, et al.
Publicado: (2013)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
por: Besse, Lenka, et al.
Publicado: (2015)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
por: Smetana, Jan, et al.
Publicado: (2014)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
por: Radocha, Jakub, et al.
Publicado: (2018)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2023)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
por: Bútová, Romana, et al.
Publicado: (2021)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

MicroRNAs in urine are not biomarkers of multiple myeloma
por: Sedlaříková, Lenka, et al.
Publicado: (2015)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
por: Smetana, Jan, et al.
Publicado: (2018)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022)

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Hajek, Roman, et al.
Publicado: (2020)

OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients
por: Radocha, Jakub, et al.
Publicado: (2021)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
por: op Bruinink, Davine Hofste, et al.
Publicado: (2020)

Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma
por: Deulofeu, Meritxell, et al.
Publicado: (2019)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Surface‐modified nanosilica–chitinase (SiNp‐Chs)‐doped nano enzyme conjugate and its synergistic pesticidal activity with plant extracts against armyworm Spodoptera litura (Fab.) (Lepidoptera: Noctuidae)
por: Narendrakumar, G., et al.
Publicado: (2021)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Ribavirin Does Not Impair the Suppressive Activity of Foxp3(+)CD4(+)CD25(+) Regulatory T Cells
por: Lee, Jeewon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_albhfgoa9mrsd46k3rk3l0kert